EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study-Reference-Cited by-同舟云学术

EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study

Published:2024-03 Issue:2 Volume:62 Page:262-268
ISSN:2212-5345
Container-title:Respiratory Investigation
language:en
Short-container-title:Respiratory Investigation

Author:

Araki Taisuke^ORCID,Kanda Shintaro^ORCID,Obara Miho,Agatsuma Toshihiko^ORCID,Kakizaki Yumiko,Hama Mineyuki,Yamamoto Hiroshi,Takada Munetake,Yamamoto Manabu,Matsuo Akemi^ORCID,Kondo Daichi,Komatsu Masamichi^ORCID,Sonehara Kei,Tateishi Kazunari,Hanaoka Masayuki,Koizumi Tomonobu^ORCID

Publisher

Elsevier BV

Reference26 articles.

1. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

2. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

3. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-A meta-analysis;Lee;J Thorac Oncol,2017

4. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study;Yang;J Clin Oncol,2023

5. Nivolumab (NIVO) + chemotherapy vs chemotherapy in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs);Mok;Ann Oncol,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2024-07-15

2. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study;Biomedicines;2024-06-25